Prof. Dr. med. Lukas Flatz
Oberarzt und Gruppenleiter
Oberarzt/Oberärztin
Dermatologie | Venerologie | Allergologie · Dept. IV
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum A, Purde M, Abdou M, Sinnberg T, Hofmeister K, Pop O, Hasan A, Bauer J, Cheng H, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer B, Driessen C, Schürch C, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy A, Schneider T, Brutsche M, Sette A, Lenz T, Walz J, Rammensee H, Früh M, Jäger E, Becher B, Tufman A, Núñez N, Jörger M, Flatz L. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade. Am J Respir Crit Care Med 2024; 210:919-930.
01.10.2024Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
01.10.2024Am J Respir Crit Care Med 2024; 210:919-930
Wyss Nina, Berner Fiamma, Walter Vincent, Jochum Ann-Kristin, Purde Mette T, Abdou Marie-Therese, Sinnberg Tobias, Hofmeister Kathrin, Pop Oltin, Hasan Ali, Bauer Jens, Cheng Hung-Wei, Lütge Mechthild, Klümper Niklas, Diem Stefan, Kosaloglu-Yalcin Zeynep, Zhang Yizheng, Sellmer Laura, Macek Boris, Karbach Julia, König David, Läubli Heinz, Zender Lars, Meyer Britta S, Driessen Christoph, Schürch Christian M, Jochum Wolfram, Amaral Teresa, Heinzerling Lucie M, Cozzio Antonio, Hegazy AhN, Schneider Tino, Brutsche Martin, Sette Alessandro, Lenz Tobias L, Walz Juliane Sarah, Rammensee Hans-Georg, Früh Martin, Jäger Elke, Becher Burkhard, Tufman Amanda, Núñez Nicolás Gonzalo, Jörger Markus, Flatz Lukas
Intratumoral administration of daromun in non-melanoma skin cancer: Preliminary results from a phase 2 non-randomized controlled trial.
Flatz L, Wagner N, Denisjuk N, Peter D, Nadal L, Puca E, Elia G, Covelli A, Neri D, Cozzio A. Intratumoral administration of daromun in non-melanoma skin cancer: Preliminary results from a phase 2 non-randomized controlled trial. J Eur Acad Dermatol Venereol 2024
22.06.2024Intratumoral administration of daromun in non-melanoma skin cancer: Preliminary results from a phase 2 non-randomized controlled trial.
22.06.2024J Eur Acad Dermatol Venereol 2024
Flatz Lukas, Wagner Nikolaus, Denisjuk Natalja, Peter Duner, Nadal Lisa, Puca Emanuele, Elia Giuliano, Covelli Alfredo, Neri Dario, Cozzio Antonio
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
Knopf P, Stowbur D, Hoffmann S, Hermann N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D, Krishnamachary B, Sinharay S, Fehrenbacher B, Gonzalez-Menendez I, Reckmann F, Bomze D, Flatz L, Kramer D, Schaller M, Forchhammer S, Bhujwalla Z, Quintanilla-Martinez L, Schulze-Osthoff K, Pagel M, Fransen M, Röcken M, Martins A, Pichler B, Ghoreschi K, Kneilling M. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol Cancer 2023; 22:207.
15.12.2023Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
15.12.2023Mol Cancer 2023; 22:207
Knopf Philipp, Stowbur Dimitri, Hoffmann Sabrina Hl, Hermann Natalie, Maurer Andreas, Bucher Valentina, Poxleitner Marilena, Tako Bredi, Sonanini Dominik, Krishnamachary Balaji, Sinharay Sanhita, Fehrenbacher Birgit, Gonzalez-Menendez Irene, Reckmann Felix, Bomze David, Flatz Lukas, Kramer Daniela, Schaller Martin, Forchhammer Stephan, Bhujwalla Zaver M, Quintanilla-Martinez Leticia, Schulze-Osthoff Klaus, Pagel Mark D, Fransen Marieke F, Röcken Martin, Martins André F, Pichler Bernd, Ghoreschi Kamran, Kneilling Manfred
A replicating LCMV-based vaccine for the treatment of solid tumors.
Purde M, Cupovic J, Palmowski Y, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou M, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger K, Bald T, Schietinger A, Schürch C, Ring S, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. Mol Ther 2023
05.12.2023A replicating LCMV-based vaccine for the treatment of solid tumors.
05.12.2023Mol Ther 2023
Purde Mette-Triin, Cupovic Jovana, Palmowski Yannick A, Makky Ahmad, Schmidt Sarah, Rochwarger Alexander, Hartmann Fabienne, Stemeseder Felix, Lercher Alexander, Abdou Marie-Therese, Bomze David, Besse Lenka, Berner Fiamma, Tüting Thomas, Hölzel Michael, Bergthaler Andreas, Kochanek Stefan, Ludewig Burkhard, Lauterbach Henning, Orlinger Klaus K, Bald Tobias, Schietinger Andrea, Schürch Christian M, Ring Sandra Stephanie, Flatz Lukas
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler T, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. J Am Acad Dermatol 2023
01.12.2023Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
01.12.2023J Am Acad Dermatol 2023
Wagner Nikolaus, Knierim Sarah M, Luttermann Felix, Metzler Gisela, Yazdi Amir Sadegh, Bauer Jürgen, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Amaral Teresa, Garbe Claus, Eigentler Thomas Kurt, Forchhammer Stephan, Flatz Lukas
Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma.
Nübel C, Amaral T, Leiter U, Flatz L, Forschner A. Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma. Front Oncol 2023; 13:1256800.
30.11.2023Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma.
30.11.2023Front Oncol 2023; 13:1256800
Nübel Charlotte, Amaral Teresa, Leiter Ulrike, Flatz Lukas, Forschner Andrea
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Eur J Cancer 2023; 196:113425.
21.11.2023Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
21.11.2023Eur J Cancer 2023; 196:113425
Wagner Nikolaus, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, Fuchß Milena, Ring Natalie, Stäger Ramon, Zellweger Caroline, Ebel Chiara, Kimeswenger Susanne, Oellinger Angela, Amaral Teresa, Forschner Andrea, Leiter Ulrike, Klumpp Bernhard, Hoetzenecker Wolfram, Terheyden Patrick, Mangana Joanna, Loquai Carmen, Cozzio Antonio, Garbe Claus, Meier Friedegund, Eigentler Thomas Kurt, Flatz Lukas
Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients.
Lichtensteiger C, Koblischke M, Berner F, Jochum A, Sinnberg T, Balciunaite B, Purde M, Walter V, Abdou M, Hofmeister K, Kohler P, Vernazza P, Albrich W, Kahlert C, Zoufaly A, Traugott M, Kern L, Pietsch U, Kleger G, Filipovic M, Kneilling M, Cozzio A, Pop O, Bomze D, Bergthaler A, Hasan A, Aberle J, Flatz L. Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients. J Autoimmun 2023; 140:103118.
10.10.2023Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients.
10.10.2023J Autoimmun 2023; 140:103118
Lichtensteiger Christa, Koblischke Maximilian, Berner Fiamma, Jochum Ann-Kristin, Sinnberg Tobias, Balciunaite Beatrice, Purde Mette-Triin, Walter Vincent, Abdou Marie-Therese, Hofmeister Kathrin, Kohler Philipp, Vernazza Pietro L, Albrich Werner, Kahlert Christian, Zoufaly Alexander, Traugott Marianna T, Kern Lukas, Pietsch Urs, Kleger Gian-Reto, Filipovic Miodrag, Kneilling Manfred, Cozzio Antonio, Pop Oltin, Bomze David, Bergthaler Andreas, Hasan Ali, Aberle Judith, Flatz Lukas
[Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab].
Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A. [Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab]. J Dtsch Dermatol Ges 2023; 21:1137-1147.
01.10.2023[Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab].
01.10.2023J Dtsch Dermatol Ges 2023; 21:1137-1147
Jasper Sophie, Keim Ulrike, Leiter Ulrike, Amaral Teresa, Flatz Lukas, Forschner Andrea
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1395.
01.09.2023Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
01.09.2023Nat Cancer 2023; 4:1395
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
Berner F, Flatz L. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis. Immunol Rev 2023; 318:37-50.
07.08.2023Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
07.08.2023Immunol Rev 2023; 318:37-50
Berner Fiamma, Flatz Lukas
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1292-1308.
31.07.2023Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
31.07.2023Nat Cancer 2023; 4:1292-1308
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Prognosis in stage II melanoma of the head and neck depends on the histological subtype.
Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A. Prognosis in stage II melanoma of the head and neck depends on the histological subtype. J Dtsch Dermatol Ges 2023; 21:1137-1146.
23.07.2023Prognosis in stage II melanoma of the head and neck depends on the histological subtype.
23.07.2023J Dtsch Dermatol Ges 2023; 21:1137-1146
Jasper Sophie, Keim Ulrike, Leiter Ulrike, Amaral Teresa, Flatz Lukas, Forschner Andrea
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. J Am Acad Dermatol 2023; 89:1072-1074.
22.07.2023EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
22.07.2023J Am Acad Dermatol 2023; 89:1072-1074
Amaral Teresa, Pop Oltin Tiberiu, Chatziioannou Eftychia, Sinnberg Tobias, Niessner Heike, Zhao Jing Hua, Ring Sandra Stephanie, Jörger Markus, Schroeder Christopher, Armeanu-Ebinger Sorin, Cozzio Antonio, Leiter Ulrike, Thomas Ioannis, Jochum Wolfram, Garbe Claus, Forchhammer Stephan, Levesque Mitchell Paul, Mangana Joanna, Hölzel Michael, Dummer Reinhard, Schürch Christian M, Forschner Andrea, Flatz Lukas
Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage.
Aebischer V, Abu-Ghazaleh A, Metzler G, Riedl L, Garbe C, Flatz L, Eigentler T, Forchhammer S. Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage. Pigment Cell Melanoma Res 2023; 36:512-521.
20.07.2023Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage.
20.07.2023Pigment Cell Melanoma Res 2023; 36:512-521
Aebischer Valentin, Abu-Ghazaleh Amar, Metzler Gisela, Riedl Lena, Garbe Claus, Flatz Lukas, Eigentler Thomas Kurt, Forchhammer Stephan
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine 2023; 93:104644.
07.06.2023Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
07.06.2023EBioMedicine 2023; 93:104644
Chatziioannou Eftychia, Roßner Jana, Aung Thazin New, Rimm David L, Niessner Heike, Keim Ulrike, Serna-Higuita Lina María, Bonzheim Irina, Kuhn Cuellar Luis, Westphal Dana, Steininger Julian, Meier Friedegund, Pop Oltin Tiberiu, Forchhammer Stephan, Flatz Lukas, Eigentler Thomas Kurt, Garbe Claus, Röcken Martin, Amaral Teresa, Sinnberg Tobias
[49. Jahrestagung der "Arbeitsgemeinschaft Dermatologische Forschung" (ADF) in Innsbruck].
Buhl T, Fabri M, Stary G, Flatz L, Erpenbeck L, Eyerich S. [49. Jahrestagung der "Arbeitsgemeinschaft Dermatologische Forschung" (ADF) in Innsbruck]. J Dtsch Dermatol Ges 2023; 21:709-710.
01.06.2023[49. Jahrestagung der "Arbeitsgemeinschaft Dermatologische Forschung" (ADF) in Innsbruck].
01.06.2023J Dtsch Dermatol Ges 2023; 21:709-710
Buhl Timo, Fabri Mario, Stary Georg, Flatz Lukas, Erpenbeck Luise, Eyerich Stefanie
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez S, Torres F, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. Am J Clin Dermatol 2023; 24:453-467.
04.05.2023Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
04.05.2023Am J Clin Dermatol 2023; 24:453-467
Chatziioannou Eftychia, Leiter Ulrike, Thomas Ioannis, Keim Ulrike, Seeber Olivia, Meiwes Andreas, Boessenecker Isabell, Gonzalez Stephanie Sanchez, Torres Francisco Merraz, Niessner Heike, Sinnberg Tobias, Forschner Andrea, Flatz Lukas, Amaral Teresa
Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S, Schroeder C, Broche J, Sinnberg T, Bonzheim I, Süsskind D, Flatz L, Forschner A. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. Front Oncol 2023; 13:1167791.
03.05.2023Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
03.05.2023Front Oncol 2023; 13:1167791
Reiter Selina, Schroeder Christopher, Broche Julian, Sinnberg Tobias, Bonzheim Irina, Süsskind Daniela, Flatz Lukas, Forschner Andrea
imaging of CD8 T cells in metastatic cancer patients: first clinical experience with simultaneous [Zr]Zr-Df-IAB22M2C PET/MRI.
Schwenck J, Sonanini D, Seyfried D, Ehrlichmann W, Kienzle G, Reischl G, Krezer P, Wilson I, Korn R, Gonzalez-Menendez I, Quintanilla-Martinez L, Seith F, Forschner A, Eigentler T, Zender L, Röcken M, Pichler B, Flatz L, Kneilling M, la Fougere C. imaging of CD8 T cells in metastatic cancer patients: first clinical experience with simultaneous [Zr]Zr-Df-IAB22M2C PET/MRI. Theranostics 2023; 13:2408-2423.
17.04.2023imaging of CD8 T cells in metastatic cancer patients: first clinical experience with simultaneous [Zr]Zr-Df-IAB22M2C PET/MRI.
17.04.2023Theranostics 2023; 13:2408-2423
Schwenck Johannes, Sonanini Dominik, Seyfried Dominik, Ehrlichmann Walter, Kienzle Gabriele, Reischl Gerald, Krezer Pascal, Wilson Ian D, Korn Ron, Gonzalez-Menendez Irene, Quintanilla-Martinez Leticia, Seith Ferdinand, Forschner Andrea, Eigentler Thomas Kurt, Zender Lars, Röcken Martin, Pichler Bernd, Flatz Lukas, Kneilling Manfred, la Fougere Christian